Abstract
GPIIb / IIIa receptor antagonists block fibrinogen binding to platelets and as a result inhibit platelet aggregation. They are very potent inhibitors due to the critical role fibrinogen binding plays in platelet aggregation. When given intravenously these drugs have been shown to be very effective as adjuvant therapy in percutaneous coronary intervention and in acute coronary syndromes. However, despite being as potent as their intravenous counterparts, all of the oral inhibitors showed no benefit or even increased mortality in clinical trials. There are a number of reasons for their failure. The target was different, chronic treatment to prevent thrombotic events as opposed to short-term treatment to prevent acute events and as a result, different dosing regimens were used. The acute use aims for a high level of inhibition (80- 90%) while the chronic use produced lower levels of inhibition. Many of the oral inhibitors had low bioavailability that led to a large peak-trough difference. Most GPIIb / IIIa antagonists have the ability to activate platelets through a GPIIb / IIIa-mediated process. This is known as partial agonism. In the presence of high drug levels, such as during an infusion this is not a problem, however combined with the low trough levels with oral inhibitors this can lead to an increase in platelet aggregation. Other problems include drug-induced conformational changes in GPIIb / IIIa (ligandregulated binding sites) and possible pharmacogenomics effects in the response to the drugs, in particular the PlA polymorphism in GPIIb / IIIa. By addressing these issues it is possible for a new generation of oral GPIIb / IIIa antagonist to be developed.
Keywords: gpIIb IIIa antagonists, platelet aggregation, pharmacogenomics
Current Pharmaceutical Design
Title: Oral GPIIb / IIIa Antagonists: What Went Wrong?
Volume: 10 Issue: 14
Author(s): Dermot Cox
Affiliation:
Keywords: gpIIb IIIa antagonists, platelet aggregation, pharmacogenomics
Abstract: GPIIb / IIIa receptor antagonists block fibrinogen binding to platelets and as a result inhibit platelet aggregation. They are very potent inhibitors due to the critical role fibrinogen binding plays in platelet aggregation. When given intravenously these drugs have been shown to be very effective as adjuvant therapy in percutaneous coronary intervention and in acute coronary syndromes. However, despite being as potent as their intravenous counterparts, all of the oral inhibitors showed no benefit or even increased mortality in clinical trials. There are a number of reasons for their failure. The target was different, chronic treatment to prevent thrombotic events as opposed to short-term treatment to prevent acute events and as a result, different dosing regimens were used. The acute use aims for a high level of inhibition (80- 90%) while the chronic use produced lower levels of inhibition. Many of the oral inhibitors had low bioavailability that led to a large peak-trough difference. Most GPIIb / IIIa antagonists have the ability to activate platelets through a GPIIb / IIIa-mediated process. This is known as partial agonism. In the presence of high drug levels, such as during an infusion this is not a problem, however combined with the low trough levels with oral inhibitors this can lead to an increase in platelet aggregation. Other problems include drug-induced conformational changes in GPIIb / IIIa (ligandregulated binding sites) and possible pharmacogenomics effects in the response to the drugs, in particular the PlA polymorphism in GPIIb / IIIa. By addressing these issues it is possible for a new generation of oral GPIIb / IIIa antagonist to be developed.
Export Options
About this article
Cite this article as:
Cox Dermot, Oral GPIIb / IIIa Antagonists: What Went Wrong?, Current Pharmaceutical Design 2004; 10 (14) . https://dx.doi.org/10.2174/1381612043384673
DOI https://dx.doi.org/10.2174/1381612043384673 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Vascular Pharmacology Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology NO to Breast: When, Why and Why Not?
Current Pharmaceutical Design Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Iridoids Analysis by Different Analytical Techniques and its Role as Pharmacologic Agents: A Review
Current Bioactive Compounds Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes
Current Enzyme Inhibition Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Placebo Preparation for the Proper Clinical Trial of Herbal Medicine - Requirements, Verification and Quality Control
Recent Patents on Inflammation & Allergy Drug Discovery The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design